NCT00347711

Brief Summary

To evaluate the effects of Intravitreal Bevacizumab in macular edema in retinal vascular occlusion.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2006

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2006

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2006

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

June 30, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 4, 2006

Completed
Last Updated

June 3, 2024

Status Verified

May 1, 2024

Enrollment Period

Same day

First QC Date

June 30, 2006

Last Update Submit

May 31, 2024

Conditions

Interventions

Eligibility Criteria

Age40 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Vascular occlusion and edema macular diagnosticated by fluorescein angiography and coherent optic tomography

You may not qualify if:

  • Previous surgery
  • Uveitis
  • Glaucoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asociacion para Evitar la Ceguera en Mexico

México, D.F. Mexico, 04030, Mexico

Location

MeSH Terms

Conditions

Macular Edema

Interventions

Intravitreal Injections

Condition Hierarchy (Ancestors)

Macular DegenerationRetinal DegenerationRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Injections, IntraocularInjectionsDrug Administration RoutesDrug TherapyTherapeutics

Study Officials

  • Griselda Alvarez, Fellow

    Asociación para Evitar la Ceguera en México

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 30, 2006

First Posted

July 4, 2006

Study Start

June 1, 2006

Primary Completion

June 1, 2006

Study Completion

June 1, 2006

Last Updated

June 3, 2024

Record last verified: 2024-05

Locations